Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review

Metastatic urothelial carcinoma (mUC) has a poor prognosis with a 5-year survival probability of 4.8%. The mainstay of first-line treatment is platinum-based chemotherapy. Second-line therapy involves immune checkpoint inhibitors or a fibroblast growth factor receptor (FGFR) inhibitor, erdafitinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Katherine Emilie Rhoades, Hitron, Emilie Elise, Russler, Greta A, Baumgarten, Deborah A, Bilen, Mehmet Asim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208383/
https://www.ncbi.nlm.nih.gov/pubmed/35756183
http://dx.doi.org/10.4103/JIPO.JIPO_22_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208383/
https://www.ncbi.nlm.nih.gov/pubmed/35756183
http://dx.doi.org/10.4103/JIPO.JIPO_22_19

Ejemplares similares